Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection is also described.
1. A compound having a structure according to Formula I:
wherein
X 2 is a member selected from
wherein
R 1 , R 2 , R 3 , R 4 , and R 5 are members independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl;
Z 2 is a member selected from substituted or unsubstituted alkenyl, substituted or unsubstituted pyridinyl, and substituted or unsubstituted phenyl;
with the proviso that when R 1 is —(CH 2 ) 16 —CH 3 , then Z 2 is not unsubstituted pyridinyl,
2. The compound according to claim 1 , wherein X 2 is
R 1 is substituted or unsubstituted alkyl.
3. The compound according to claim 2 , wherein R 1 is a substituted or unsubstituted C 8 -C 20 alkyl moiety.
4. The compound according to claim 2 , wherein R 1 is haloalkyl.
5. The compound according to claim 4 , wherein R 1 is a member selected from chloromethyl and dichloromethyl.
6. A pharmaceutical composition of claim 1 and a pharmaceutically acceptable carrier.
7. A method for the treatment of a disorder of the nervous system in an animal or human comprising the step of administering to an animal or human in need thereof a therapeutically effective amount of the compound of claim 1 , wherein said disorder of the nervous system is selected from the group consisting of Parkinson's disease, ischemia, stroke, Alzheimer's disease, depression, anxiety, encephalitis, meningitis, amyotrophic lateral sclerosis, trauma, spinal cord injury, and nerve injury.
8. A method of synthesizing a synthetic ganglioside compound of claim 1 , wherein the steps of synthesis of the saccharide moiety comprise:
contacting an acceptor molecule comprising a sphingoid moiety and a glucose (Glc) with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form:
contacting the
with a transsialidase enzyme and a sialic acid (NANA) donor molecule to form:
contacting the
with a N-acetyl galactose (GalNAc)-transferase enzyme and a GaINAc donor molecule to form:
contacting the
with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form:
contacting the
with a fatty acid moiety under conditions sufficient to form a ganglioside.
9. A compound having a structure according to Formula II:
wherein
X 3 is a member selected from
wherein
R 10 , R 11 , R 12 , R 13 , and R 14 are members independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalky;
J 1 is —NR 15 R 16
wherein
R 15 and R 16 are members independently selected from substituted or unsubstituted alkyl; and
K 1 is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
10. The compound according to claim 9 , wherein at least one member selected from R 15 and R 16 is —(CH 2 ) 7 —CH 3 .
11. The compound according to claim 9 , wherein K 1 is substituted or unsubstituted aryl.
12. The compound according to claim 11 , wherein K 1 is substituted or unsubstituted phenyl.
13. The compound according to claim 9 , wherein X 3 is
R 10 is substituted or unsubstituted alkyl.
14. The compound according to claim 13 , wherein R 10 is a substituted or unsubstituted alkyl moiety.
15. The compound according to claim 13 , wherein R 10 is haloalkyl.
16. The compound according to claim 15 , wherein R 10 is a member selected from chloromethyl and dichloromethyl.
17. A pharmaceutical composition of claim 9 and a pharmaceutically acceptable carrier.
18. A method for the treatment of a disorder of the nervous system in an animal or human comprising the step of administering to an animal or human in need thereof a therapeutically effective amount of the compound of claim 9 wherein said disorder of the nervous system is selected from the group consisting of Parkinson's disease, ischemia, stroke, Alzheimer's disease, depression, anxiety, encephalitis, meningitis, amyotrophic lateral sclerosis, trauma, spinal cord injury, and nerve injury.
19. A method of synthesizing a synthetic ganglioside compound of claim 9 , wherein the steps of synthesis of the saccharide moiety comprise:
contacting an acceptor molecule comprising a sphingoid moiety and a glucose (Glc) with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form:
contacting the
with a transsialidase enzyme and a sialic acid (NANA) donor molecule to form:
contacting the
with a N-acetyl galactose (GalNAc)-transferase enzyme and a GalNAc donor molecule to form:
contacting the
with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form:
contacting the
with a fatty acid moiety under conditions sufficient to form a ganglioside.
20. A compound having a structure according to Formula III:
wherein
X 4 is substituted or unsubstituted alkyl, —C(=M 2 )R 20 ,—C(=M 2 )—Q 2 -R 20 ,—SO 2 R 20 ;
wherein R 20 is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;
M 2 and Q 2 are members independently selected from O, NR 21 and S;
wherein
R 21 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl; and
A 1 and A 2 are members independently selected from H, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl;
K 2 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroarylalkyl;
with the proviso that if A 1 is —(CH 2 ) 7 —CH 3 , A 2 is —(CH 2 ) 7 —CH 3 , X 4 is —C(═O)R 20 , and R 20 is —(CH 2 ) 16 —CH 3 , then K 2 is not unsubstituted phenyl.
21. The compound according to claim 20 , wherein X 4 is —C(═O)R 20 , and R 20 is substituted or unsubstituted alkyl.
22. The compound according to claim 21 , wherein X 4 is
23. The compound according to claim 20 , wherein A 1 and A 2 are independently selected from substituted or unsubstituted alkyl.
24. The compound according to claim 20 , wherein A 1 and A 2 are —(CH 2 ) 7 —CH 3 .
25. The compound according to claim 20 , wherein K 2 is substituted or unsubstituted aryl.
26. The compound according to claim 25 , wherein K 2 is phenyl.
27. A pharmaceutical composition of claim 20 and a pharmaceutically acceptable carrier.
28. A method for the treatment of a disorder of the nervous system in an animal or human comprising the step of administering to an animal or human in need thereof a therapeutically effective amount of the compound of claim 20 , wherein said disorder of the nervous system is selected from the group consisting of Parkinson's disease, ischemia, stroke, Alzheimer's disease, depression, anxiety, encephalitis, meningitis, amyotrophic lateral sclerosis, trauma, spinal cord injury, and nerve injury.
29. A method of synthesizing a synthetic ganglioside compound of claim 20 , wherein the steps of synthesis of the saccharide moiety comprise:
contacting an acceptor molecule comprising a sphingoid moiety and a glucose (Glc) with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form:
contacting the
with a transsialidase enzyme and a sialic acid (NANA) donor molecule to form:
contacting the
with a N-acetyl galactose (GalNAc)-transferase enzyme and a GalNAc donor molecule to form:
contacting the
with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form:
contacting the
with a fatty acid moiety under conditions sufficient to form a ganglioside.